Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Monday, February 26, 2024 | Back issues
Courthouse News Service Courthouse News Service

Pfizer Jab 97% Effective Against Symptomatic Covid: Study

Pfizer/BioNTech's coronavirus vaccine offers more protection than earlier thought with effectiveness in preventing symptomatic disease reaching 97%, according to real-world evidence published Thursday by the pharmaceutical companies.

BERLIN (AFP) — Pfizer/BioNTech's coronavirus vaccine offers more protection than earlier thought with effectiveness in preventing symptomatic disease reaching 97%, according to real-world evidence published Thursday by the pharmaceutical companies.

Using data from January 17 to March 6 from Israel's national vaccination campaign, Pfizer/BioNTech found that prevention against asymptomatic disease also reached 94%.

An earlier real-world study using data from between December 20, 2020, and February 1, 2021, had showed effectiveness at preventing symptomatic disease at 94% and asymptomatic illness at 92%.

"This comprehensive real-world evidence ... can be of importance to countries around the world as they advance their own vaccination campaigns one year after the World Health Organization declared COVID-19 a pandemic," the two pharmaceutical companies said in a statement.

Israel's inoculation campaign is the fastest in the world, with about 40% of the population already fully vaccinated against the virus.

Israel, which launched its vaccination campaign in December, has given the recommended two jabs of the Pfizer/BioNTech vaccine to just under four million of its roughly 9 million people.

More than 5 million have received one shot.

"Incidence rates in the fully vaccinated population have massively dropped compared to the unvaccinated population, showing a marked decline in hospitalized cases due to Covid-19," said Israel's Ministry of Health director Yeheskel Levy.

© Agence France-Presse

Categories / Health, Science

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...